What Anumana does
Anumana develops AI algorithms, including its ECG-AI LEF product, that analyze electrocardiogram signals to detect low ejection fraction and other cardiac conditions that are difficult for clinicians to see directly. The technology integrates into electronic health record and ECG management systems and is designed for on-premise deployment inside health systems rather than the cloud. Anumana was founded in 2021 as a joint venture between the Mayo Clinic Platform and nference, and it is based in Cambridge, Massachusetts.
Anumana is a healthcare tool on Falcoscan. AI that reads ECG signals to detect cardiac disease beyond human perception. Falcoscan rates Anumana with an Opportunity score of 86/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Anumana is founded in 2021, currently at Series_c stage. Pricing: Paid.